This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus DNA.
Positive hepatitis b surface antigen and hepatitis b antibody > 0.5 year;
Age from 18 to 65 years old;
Serum Alanine Aminotransferase(ALT) ≤1×ULN at least 12 weeks;
Positive Hepatitis b virus(HBV);
Other active liver diseases;
Hepatocellular carcinoma or other malignancy;
Pregnancy or lactation;
Human immunodeficiency virus infection or congenital immune deficiency diseases; 5.Severe diabetes, autoimmune diseases; 6.Other important organ dysfunctions; 7.Using glucocorticoid; 8.Patients can not follow-up; 9.Investigator considering inappropriate.